ISOFOL 12.84 SEK (-0.16) 03 Dec 2021 17:29 NOMINATION COMMITTEE The Nomination Committee's task is to prepare and prepare proposals for the election of and fees to the Chairman of the Board, Board members, committee members and auditors, the latest previously proposed by the Audit Committee. The members of the Nomination Committee shall safeguard the interests of all shareholders and not unauthorisedly disclose what has occurred in the Nomination Committee's work. The Chairman of the Board or another Board member shall not be the Chairman of the Nomination Committee. The Nomination Committee meets when necessary, but at least once a year. The term of office of the appointed Nomination Committee shall run until a new Nomination Committee has been appointed. No later than six months before the Annual General Meeting, the members of the Nomination Committee shall be published on Isofol's website. According to the principles for appointing a nomination committee in Isofol Medical AB (publ) that were adopted at the Annual General Meeting on 23 June 2021, the Nomination Committee for the 2022 Annual General Meeting shall consist of four members, one of whom shall be the Chairman of the Board. The other three members prior to the 2022 Annual General Meeting consist of representatives appointed by the three largest shareholders in the company as of September 30, 2021. The term of office of the appointed Nomination Committee shall run until a new Nomination Committee has been appointed. The Nomination Committee prior to the 2022 Annual General Meeting Isofol's Nomination Committee for the 2022 Annual General Meeting consists of four members: ● Malin Björkmo, Chairman of the Nomination Committee, appointed by Handelsbanken Fonder ● Lars Lind, appointed by Hans Enocson ● Ulrik Grönvall, appointed by Swedbank Robur Fonder ● Mats-Ola Palm, appointed by about 12% of the votes Ahead of the 2022 Annual General Meeting The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting and on the company's website isofolmedical.com. Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to valberedningen@isofolmedical.com (heading: "Isofol's Nomination Committee") or by letter to the following address: Isofol Medical AB (publ) Att. The Nomination Committee Arvid Wallgrens Backe 20 413 46 GÖTEBORG Document The Nomination Committee's complete instructions adopted by the 2021 Annual General Meeting (42 kB) The Nomination Committee's complete instructions adopted by the 2020 Annual General Meeting (118 kB) Corporate governance Corporate governance report Articles of association Annual General Meetings The board The task of the board Remuneration Committee Compensation Incentive program Audit Committee Auditor Nomination Committee The cord Om Isofol Isofol Medical AB (publ) är ett biotechbolag verksamt inom onkologi som utvecklar cancerläkemedlet arfolitixorin. Arfolitixorin är en ny läkemedelskandidat som främst är avsett för behandling av kolorektalcancer (CRC), en av de vanligaste formerna av cancer. Isofol utvecklar även arfolitixorin för så kallad räddningsbehandling efter högdosbehandling med cellgiftet metotrexat vid osteosarkom (bencancer). Kontakt Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20 413 46 Göteborg Sverige Telefon: +46 (0)31 7972280 E-post: info@isofolmedical.com Nyhetsbrev och integritetspolicy Sign up here to receive news, press releases & information and consent to Isofol's processing of your personal data in accordance with the company's privacy policy. Isofol's privacy policy (general) Isofol's privacy policy (clinical trials) © 2018 Isofol Medical AB (publ) Biotech Cente, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden Isofol´s Glossary Isofol's website uses cookies to improve and customize your visit. By continuing you accept this.Accept Read More